Publikationen (58) Publikationen von Azucena Aldaz Pastor

2024

  1. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

2023

  1. A pharmacometrics model to define docetaxel target in early breast cancer

    British Journal of Clinical Pharmacology, Vol. 89, Núm. 2, pp. 727-736

  2. Predicting Severe Haematological Toxicity in Gastrointestinal Cancer Patients Undergoing 5-FU-Based Chemotherapy: A Bayesian Network Approach

    Cancers, Vol. 15, Núm. 17

  3. Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma

    Pancreatology, Vol. 23, Núm. 4, pp. 411-419

2022

  1. Impact of the Acceptance of the Recommendations Made by a Meropenem Stewardship Program in a University Hospital: A Pilot Study

    Antibiotics, Vol. 11, Núm. 3

2021

  1. Effectiveness of Pharmacokinetic/Pharmacodynamic-Guided Meropenem Treatment in Critically Ill Patients: A Comparative Cohort Study

    Therapeutic drug monitoring, Vol. 43, Núm. 2, pp. 256-263

  2. Effects of dexmedetomidine on subthalamic local field potentials in Parkinson's disease

    British Journal of Anaesthesia, Vol. 127, Núm. 2, pp. 245-253

  3. Farmacocinética y farmacogenética en la optimización de los tratamientos en psiquiatría: Revisión sistemática

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 45, Núm. 7, pp. 84-93

2020

  1. Clinical and economic impact of clinical pharmacist interventions regarding antimicrobials on critically ill patients

    Research in Social and Administrative Pharmacy, Vol. 16, Núm. 9, pp. 1285-1289

  2. Effectiveness of adjunctive nebulized antibiotics in critically ill patients with respiratory tract infections

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 39, Núm. 2, pp. 361-368

  3. Estudio observacional de la toxicidad con diferentes formulaciones de docetaxel en pacientes con cáncer de mama

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 44, Núm. 5, pp. 192-197

  4. Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation

    European Journal of Clinical Pharmacology, Vol. 75, Núm. 10, pp. 1405-1414

  2. Mining small routine clinical data: A population pharmacokinetic model and optimal sampling times of capecitabine and its metabolites

    Journal of Pharmacy and Pharmaceutical Sciences, Vol. 22, pp. 112-121

  3. Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer

    European Journal of Clinical Pharmacology, Vol. 75, Núm. 4, pp. 529-542

  4. Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters

    Journal of Pharmacological Sciences, Vol. 140, Núm. 1, pp. 20-25

2018

  1. Evidence of clinical and economic impact of pharmacist interventions related to antimicrobials in the hospital setting

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 37, Núm. 5, pp. 799-822

  2. Influence of comedication on levetiracetam pharmacokinetics

    Therapeutic Drug Monitoring, Vol. 40, Núm. 1, pp. 130-134

  3. Influence of sex, age, and weight on levetiracetam pharmacokinetics

    Therapeutic Drug Monitoring, Vol. 40, Núm. 5, pp. 628-634

  4. Nanomedicines for pediatric cancers

    ACS Nano, Vol. 12, Núm. 8, pp. 7482-7496